Triple threat: new combo therapy targets advanced endometrial cancer
NCT ID NCT05819892
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing whether combining chemotherapy and radiation, followed by more chemotherapy plus the immunotherapy drug dostarlimab, is safe and tolerable for people with stage IIIC node-positive endometrial cancer. The study aims to see if this approach can help control the cancer after surgery. Only 21 participants will be enrolled, and the main focus is on side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
chemotherapy (paclitaxel, carboplatin, cisplatin) plus radiation therapy and dostarlimab
What this could lead to
If successful, this could point toward a new treatment option that helps control advanced endometrial cancer after surgery.
What could go wrong
This is a very early Phase 1 trial with only 21 participants, so it is primarily testing safety, not effectiveness. The combination may cause significant side effects and may not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact